← back to search

Lars Rombo

Science for Life Laboratory · SE
Area of research
Epidemiology · Hepatology
Research interest
Research interests include Medicine, Vaccination, Placebo, Virology, Confidence interval, and Postherpetic neuralgia.
h-index
citations
1,481
works
10
NIH funding
primary concept
email

Recent publications

Final analysis of the ZOE-LTFU trial to 11 years post-vaccination: efficacy of the adjuvanted recombinant zoster vaccine against herpes zoster and related complications
EClinicalMedicine 2025cited by 15position: middledoi
The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70
Clinical Infectious Diseases 2021cited by 93position: middledoi
Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials
Vaccine 2019cited by 63position: middledoi
Non-typeable Haemophilus influenzae protein vaccine in adults with COPD: A phase 2 clinical trial
Vaccine 2019cited by 54position: middledoi
Clinical impact of a non-typeable Haemophilus influenzae (NTHi) adjuvanted vaccine in adults with chronic obstructive pulmonary disease (COPD)
2019cited by 2position: middledoi
Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group
Vaccine 2018cited by 62position: middledoi
Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older
New England Journal of Medicine 2016cited by 1,030position: middledoi
Hepatitis A vaccine for immunosuppressed patients with rheumatoid arthritis: A prospective, open-label, multi-centre study
Travel Medicine and Infectious Disease 2014cited by 78position: middledoi
Cross-Protective Capacity of Japanese Encephalitis (JE) Vaccines Against Circulating Heterologous JE Virus Genotypes
Clinical Infectious Diseases 2012cited by 75position: middledoi
Safety of a 2-dose Regimen of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine Manufactured With Recombinant Human Albumin
The Pediatric Infectious Disease Journal 2012cited by 9position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Paul Walker · University of Liverpool2 papers (2019–2019)Stuart Schembri · University of Dundee2 papers (2019–2019) · 2 papers (2019–2019)Christopher E. Brightling · University of Leicester2 papers (2019–2019)William MacNee · The Queen's Medical Research Institute2 papers (2019–2019) · 2 papers (2019–2019)Anu Kantele · University of Helsinki2 papers (2012–2014)Tom Wilkinson · Southampton General Hospital2 papers (2019–2019)Ashwani Kumar Arora · Novartis (Switzerland)2 papers (2019–2019)Nawar Diar Bakerly · University of Manchester2 papers (2019–2019)Keir Lewis · London School of Hygiene & Tropical Medicine2 papers (2019–2019)Javier Díez‐Domingo · Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana2 papers (2012–2025) · 2 papers (2019–2019)Martin Allen · Medical College of Wisconsin2 papers (2019–2019) · 1 papers (2025–2025) · 1 papers (2025–2025)Helena Hervius Askling · Karolinska Institutet1 papers (2012–2012)Tino F. Schwarz · University of Ferrara1 papers (2025–2025) · 1 papers (2014–2014) · 1 papers (2012–2012)